A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the efficacy of anti-COVID-19 immune globulin (human)
20% (C19-IG 20%) (2 doses) versus placebo with regard to the percentage of asymptomatic
participants who remain asymptomatic, i.e., who do not develop symptomatic coronavirus
disease 2019 (COVID-19) through Day 14 as per the protocol defined criteria.